智通财经APP讯，海普瑞(002399.SZ)公告，公司全资孙公司深圳市天道医药有限公司(简称“天道医药”)近期收到阿根廷国家药品、食品和医疗器械管理局(ANMAT)签发的依诺肝素钠注射液批准通知。
公告显示，依诺肝素钠注射液适应症为：预防中高风险外科手术引起的静脉血栓栓塞性疾病，特别是接受骨科或普外手术(包括癌症手术)的患者;预防急性疾病(如急性心力衰竭、呼吸衰竭、严重感染或风湿性疾病)引起的行动限制且静脉血栓栓塞风险增加的患者的静脉血栓栓塞性疾病;治疗深静脉血栓和肺栓塞，但需溶栓治疗或手术的肺栓塞除外;活动性癌症患者深静脉血栓和肺栓塞的长期治疗及预防复发;用于血液透析体外循环中，预防血栓的形成;急性冠状动脉综合征：与阿司匹林联合，治疗不稳定型心绞痛和非ST段抬高型心肌梗死;治疗急性ST段抬高型心肌梗死，包括需要接受药物治疗或经皮冠状动脉介入治疗(PCI)的患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.